Ascend Therapeutics is now promoting Egalet’s Sprix ketorolac tromethamine nasal spray for the treatment of moderate-to-moderately severe pain to women’s healthcare providers in the US, Egalet said. According to Egalet, the companies signed the agreement allowing Ascend to promote the product in July 2017.
Egalet Chief Commercial Officer Patrick Shea commented, “Ascend’s launch of Sprix promotion to its target women’s healthcare practitioners is a key step in expanding our commercial reach as this doubles the promotional effort behind Sprix. Given the need for effective acute pain treatment options in women’s health, we believe Sprix nasal spray should be well received by their target healthcare providers.”
Ascend CEO Sunil Sehgal said, “Sprix offers an attractive product profile as a non-narcotic that provides opioid-level pain relief for our target women’s healthcare providers. Having now been trained on Sprix Nasal Spray, our representatives are out educating their target HCPs about the benefits and risks of the product.”
Read the Egalet press release.
